Indian Generics Slash Semaglutide Prices Post-Patent

What happened

Several Indian pharmaceutical companies rolled out lower-priced semaglutide medicines over the weekend, shortly after the semaglutide patent lapsed in India last week.

At least six manufacturers introduced products positioned as alternatives to Novo Nordisk’s Ozempic and Wegovy, which are used for type 2 diabetes and weight management.

Pricing and product launches

The new launches are described as cutting treatment costs by about 70% versus existing options, with pricing that the source says is unmatched globally.

Companies named in the launches include Sun Pharmaceutical, Dr Reddy’s Laboratories, Zydus Lifesciences, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Alkem Laboratories, and Eris Lifesciences.

Sun Pharmaceutical set weekly pricing for its weight-management brand Noveltreat at 900 to 2,000 rupees (about $9.58 to $21.30). For type 2 diabetes, Sun’s Sematrinity is priced at 750 to 1,300 rupees per week (about $7.99 to $13.84).

How competitors are positioning

Dr Reddy’s product Obeda is listed at roughly 4,200 rupees per month (about $44.73) for diabetes. Zydus Lifesciences introduced Semaglyn, Mashema, and Alterme, averaging about 2,200 rupees monthly (about $23.43).

Torrent Pharmaceuticals launched injectable options Sembolic and Semalix starting at 3,999 rupees per month (about $42.59). Glenmark’s GLIPIQ vial is priced at 1,300 to 1,760 rupees monthly (about $13.84 to $18.74).

Alkem Laboratories brought out Semasize, Obesema, and Hepaglide starting at 1,800 rupees per month (about $19.17). Eris Lifesciences’ Sundae vial begins at 1,290 rupees per month (about $13.74).

Why it matters now

The immediate catalyst is the patent change in India, which opened the door for multiple domestic producers to enter a market previously dominated by branded products.

For patients and healthcare providers, the near-term effect is a wider set of semaglutide choices at materially lower price points, which could influence prescribing and affordability in one of the world’s largest medicine markets.

Market context and what could change next

Analysts cited in the source expect more than 40 Indian drugmakers to introduce over 50 versions, aiming to capture part of a global obesity market projected at $100 billion by the end of the decade.

Those expectations also include ambitions to expand beyond India into Canada, Brazil, Latin America, and Turkey, though the source does not provide timelines, regulatory pathways, or launch sequencing for those markets.

Risks and uncertainties

While the weekend launches and listed prices are concrete, several key details remain unclear from the source, including how quickly supply can scale, how demand will respond across indications, and what the competitive impact will be on branded semaglutide sales in India.

International expansion plans are also not confirmed outcomes; market entry would depend on country-specific approvals, distribution, and pricing dynamics that are not described in the available information.